Wealth Enhancement Advisory Services’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-25,989
Closed -$79.3K – 4230
2026
Q2
$79.3K Buy
+25,989
New +$77.6K ﹤0.01% 3845
2025
Q3
– Sell
-24,828
Closed -$118K – 3587
2025
Q2
$118K Buy
24,828
+10,264
+70% +$55.5K ﹤0.01% 3111
2025
Q1
$72.8K Sell
14,564
-1,024
-7% -$6.49K ﹤0.01% 2814
2024
Q4
$112K Buy
15,588
+5,956
+62% +$45.5K ﹤0.01% 2793
2024
Q3
$59.1K Sell
9,632
-8
-0.1% -$54 ﹤0.01% 2607
2024
Q2
$64.1K Buy
+9,640
New +$71.1K ﹤0.01% 2441

Other funds holding ALT

Wealth Enhancement Advisory Services's ALT Position: Q3 2026 in Review

Wealth Enhancement Advisory Services sold out of Altimmune (ALT) in Q3 2026, closing a stake of 25,989 shares — an estimated $79.3K sold.

Wealth Enhancement Advisory Services first reported a position in ALT in Q2 2024 and held it in 6 quarters. The position peaked at $118K in Q2 2025. 191 funds tracked by Wall St. Rank hold ALT as of Q3 2026.

  • Wealth Enhancement Advisory Services reported no remaining Altimmune position as of Q3 2026 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 25,989 Altimmune shares in Q3 2026, an estimated $79.3K.
  • Wealth Enhancement Advisory Services first reported a position in Altimmune in Q2 2024 and held it in 6 quarters.
  • Wealth Enhancement Advisory Services's Altimmune position peaked at $118K in Q2 2025.
  • 191 funds tracked by Wall St. Rank held Altimmune as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.